52809-19-5

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinepropanoic acid, ethyl ester is used as a building block for the synthesis of various pharmaceutical compounds and organic molecules. Its unique chemical properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Food and Beverage Industry:
4-Pyridinepropanoic acid, ethyl ester is used as a flavoring agent in food and beverages. Its ability to impart specific tastes and aromas contributes to the enhancement of consumer products in this industry.
Safety Precautions:
While 4-Pyridinepropanoic acid, ethyl ester offers numerous benefits, it is crucial to handle and store this chemical with care. Its potential hazards can be mitigated through proper management and adherence to safety guidelines.

Upstream product

• 6318-43-0 3-pyridin-4-yl-propionic acid 
• 64-17-5 ethanol 
• 123293-78-7 ethyl 3-(4-pyridinyl)-(2E)-propenoate 
• 84200-06-6 3-(pyridin-4-yl)propanenitrile 
• 872-85-5 pyridine-4-carbaldehyde 
• 1120-87-2 4-bromopyridin 
• 6163-58-2 tris-(o-tolyl)phosphine 
• 140-88-5 ethyl acrylate 
• 24489-96-1 ethyl 3-(pyridin-4-yl)prop-2-enoate 
• 100-48-1 pyridine-4-carbonitrile 
• 181219-01-2 4-pyridineboronic acid pinacol ester 
• 193065-68-8 (3-ethoxy-3-oxopropyl)zinc(II) bromide 
• 1261271-95-7 C₁₀H₁₃NO₂*C₇₂H₅₂N₄O₄Zn 
• 1261271-80-0 C₁₀H₁₃NO₂*C₇₂H₅₂N₄O₄Zn 

Downstream Products

• 98594-24-2 3-(4-pyridyl)propanoic acid hydrazide 
• 6318-43-0 3-pyridin-4-yl-propionic acid 
• 64107-42-2 2-[2-(5-Methyl-1H-imidazol-4-ylmethylsulfanyl)-ethylamino]-5-pyridin-4-ylmethyl-1H-pyrimidin-4-one; hydrochloride 
• 122945-89-5 2-[2-(3-Bromo-pyridin-2-ylmethylsulfanyl)-ethylamino]-5-pyridin-4-ylmethyl-1H-pyrimidin-4-one; hydrobromide 
• 344352-02-9 1-(3-cyanophenyl)-3-(pyridin-4-ylmethyl)-1,8-naphthyridin-2(1H)-one 
• 344352-04-1 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)-1,8-naphthyridin-2(1H)-one 
• 120690-80-4 3-(pyridin-4-yl)propionaldehyde 
• 1261270-67-0 Zn((HOC₆H₄)4C₂₀H₈N₄)(EtOCOCH₂CH₂C₅H₄N) 
• 1261271-50-4 C₁₀H₁₃NO₂*C₄₈H₃₆N₄O₄Zn 
• 1261270-67-0 C₁₀H₁₃NO₂*C₄₄H₂₈N₄O₄Zn 
• 1261271-65-1 C₁₀H₁₃NO₂*C₇₂H₅₂N₄O₄Zn 
• 1261271-80-0 C₁₀H₁₃NO₂*C₇₂H₅₂N₄O₄Zn 
• 1261271-95-7 C₁₀H₁₃NO₂*C₇₂H₅₂N₄O₄Zn 
• 1261270-82-9 C₁₀H₁₃NO₂*C₆₈H₄₄N₄O₄Zn 

Relevant academic research and scientific papers

Electroreductive 4-Pyridylation of Electron-deficient Alkenes with Assistance of Ni(acac)2

An electroreductive 4-pyridylation of activated alkenes was developed in an undivided cell with the assistance of Ni(acac)2 (acac = acetylacetone). This novel protocol is compatible with a broad range of electron-poor alkenes, which are commonl

Electrochemical Hydrogenation with Gaseous Ammonia

As a carbon-free and sustainable fuel, ammonia serves as high-energy-density hydrogen-storage material. It is important to develop new reactions able to utilize ammonia as a hydrogen source directly. Herein, we report an electrochemical hydrogenation of alkenes, alkynes, and ketones using ammonia as the hydrogen source and carbon electrodes. A variety of heterocycles and functional groups, including for example sulfide, benzyl, benzyl carbamate, and allyl carbamate were well tolerated. Fast stepwise electron transfer and proton transfer processes were proposed to account for the transformation.

Synthesis and utility of dihydropyridine boronic esters

When activated by an acylating agent, pyridine boronic esters react with organometallic reagents to form a dihydropyridine boronic ester. This intermediate allows access to a number of valuable substituted pyridine, dihydropyridine, and piperidine products.

Dissection of complex molecular recognition interfaces

The synthesis of a family of zinc porphyrins and pyridine ligands equipped with peripheral H-bonding functionality has provided access to a wide range of closely related supramolecular complexes featuring between zero and four intramolecular H-bonds. An automated UV/vis titration system was used to characterize 120 different complexes, and these data were used to construct a large of number of different chemical double mutant cycles to quantify the intramolecular H-bonding interactions. The results probe the quantitative structure-activity relationship that governs cooperativity in the assembly of complex molecular recognition interfaces. Specifically, variations in the chemical structures of the complexes have allowed us to change the supramolecular architecture, conformational flexibility, geometric complementarity, the number and nature of the H-bond interactions, and the overall stability of the complex. The free energy contributions from individual H-bonds are additive, and there is remarkably little variation with architecture in the effective molarity for the formation of intramolecular interactions. Intramolecular H-bonds are not observed in complexes where they are geometrically impossible, but there are no cases where excellent geometric complementarity leads to very high affinities. Similarly, changes in conformational flexibility seem to have limited impact on the values of effective molarity (EM). The major variation that was found for all of the 48 intramolecular interactions that were examined using double mutant cycles is that the values of EM for intramolecular carboxylate ester-phenol H-bonds (200 mM) are an order of magnitude larger than those found for phosphonate diester-phenol H-bonds (30 mM). The corresponding intermolecular phosphonate diester-phenol H-bonds are 2 orders of magnitude more stable than carboxylate ester-phenol H-bonds, and the large differences in EM may be due to some kind of compensation effect, where the stronger H-bond is harder to make, because it imposes tighter constraints on the geometry of the complex.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. Thesd compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Part 3: 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2- ethoxyiminoacetamido] cephalosporins beari

Among the prepared C-3′ substituted-pyridinium cephalosporins, a series of 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-ethoxyiminoacetamido] cephalosporins bearing 4-[3-(aminoalkyl)-ureido]-1-pyridinium at C-3′ showed highly potent antibacterial activity agai

Novel 1,8-naphthyridin-2(1h)-one derivatives

The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein: A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring, B is carbon or nitrogen, R1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, R2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and m is an integer of from 1 to 8, both inclusive; or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor

Compounds of formula (I): wherein: X is a group of formula (A) or (B): and R1, R2, R3, R4, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.

PYRAZOLES AS HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2 INHIBITORS

A class of novel pyrazoles is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock

Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors

A class of novel pyrazoles is disclosed together with the use of such compounds for inhibiting sPLA2mediated release of fatty acids for treatment of conditions such as septic shock.